Join us for the latest axSpA podcast brought to you by the Immune-Mediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar, and Xenofon Baraliakos to discuss a recent study on the incidence of uveitis in patients with axSpA that were treated with bimekizumab.

Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Laura Andreoli, a Professor of Rheumatology at the University of Brescia, as they discuss her recent paper ‘The outcomes of children born to mothers with autoimmune rheumatic diseases’, published in The Lancet. Rheumatology on 11th June 2024.

Join Professor Iain McInnes and Professors Hideto Kameda and Peter Nash for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode, they discuss a paper that investigated whether the baseline neutrophil-to-lymphocyte ratio had an effect on the treatment response to filgotinib.

Join Professor Iain McInnes for the first episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest information and data in rheumatology. In this episode, he discusses two papers that aimed to advise on treatment of rheumatic diseases in a real-world setting. In our first paper, Emma Dures and her colleagues compiled the 2023 EULAR recommendations for the management of fatigue in people with inflammatory rheumatic and musculoskeletal diseases. Our second paper is from Kehinde Sunmboye and his colleagues, where they investigated the incidence of MACE in a multi-ethnic population that were treated with JAK inhibitors. To access detailed summary slides for the papers discussed today, visit imidforum.com.

Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. They discuss two highly relevant topics in the field, including the clinical response to guselkumab and the research surrounding sequential lines of b/tsDMARDs.

Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest information and data in rheumatology. In this episode, he discusses two papers that show the long-term safety and efficacy of JAK inhibitors, both of which have a study period of 6.5 years. In our first paper, Roberto Caporali and colleagues show long-term safety and efficacy data for baricitinib as an RA therapy. Our second paper is from Christina Charles-Schoeman and her colleagues, where they present long-term data on the effect of upadacitinib on laboratory parameters in people with RA. To access detailed summary slides for the papers discussed today, visit imidforum.com.

Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar and Xenofon Baraliakos to discuss the risk of acute anterior uveitis across different bDMARDs in patients with AS. Our faculty then move on to discuss another publication, which compares patient-reported outcomes (PROs) and 24-month retention rates between patients with axSpA and PsA that were treated with secukinumab.

Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest information and data in rheumatology. In this episode, he discusses two papers that that add to the knowledge of common treatments relating to RA. In our first paper, Juergen Rech and colleagues present the results of the ARIAA study, which shows that abatacept inhibits inflammation symptoms and progression to RA in high-risk patients. Our second paper is from Juergen Rech and colleagues, where they present the results of the ARIAA study which investigated whether abatacept inhibits inflammation symptoms and progression to RA in high-risk patients. To access detailed summary slides for the papers discussed today, visit imidforum.com.

Join us for the latest axSpA podcast brought to you by the CSF! This month Dr Sofia Ramiro, consultant rheumatologist and senior researcher at Leiden University Medical Centre and Zuyderland Medical Centre, is joined once again by experts with a wealth of clinical knowledge. Joining her is Hideto Kameda, Professor of Internal Medicine at Toho University as well as Atul Deodhar, Professor of Medicine and Medical Director of Rheumatology Clinics in the Division of Arthritis & Rheumatic Diseases at Oregon Health & Science University in Portland, USA. Also joining this insightful group is Xenofon Baraliakos, Professor of Internal Medicine and Rheumatology at the Ruhr-University in Bochum, and Medical Director of the rheumatology centre Rheumazentrum Ruhrgebiet in Herne, Germany In the first paper discussed, the authors compared the efficacy and safety of bimekizumab with biologic/targeted synthetic disease-modifying antirheumatic drugs in nr-axSpA and AS. Our second paper then goes on to identify distinct clinical clusters based on patient demographics and baseline clinical indicators from the clinical development programme of secukinumab in patients with a variety of rheumatological conditions.

Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, they focus on the updated 2023 EULAR recommendations for PsA and the improvement of PROs reported in a Phase 2 trial with deucravacitinib.

Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar and Xenofon Baraliakos to discuss the long-term etanercept response in patients with radiographic axSpA and the comparison of tofacitinib and adalimumab in a real-world clinical context.